In this review, we have presented molecular insights into the clinical impacts of oncogenic alterations and the effects of overexpression of transcription factors (KRAS, APC, c-Myc, P53, and HIF1-α), metabolite transporters (GLUT1), and glycolytic enzymes (HK2, PKM2, PDK1, and LDH) on the Warburg effect in CRC cells. This evidence concerns the gene KRAS and colorectal carcinoma.